More on LGND
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $68.53 |
|
|||
| Open | $68.50 | ||||
| 52 Wk High | $139.79 | ||||
| 52 Wk Low | $82.07 | ||||
| Day High | $71.16 | ||||
| Day Low | $68.50 | ||||
| P/E | 162.53 | ||||
| EPS | $0.43 | ||||
| Volume | 140,672 | ||||
- Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
- Form 8-K LIGAND PHARMACEUTICALS For: Apr 17
- Ligand Pharma (LGND) Announces New Topiramate Injection Data Presented
- Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
- Ligand Pharma (LGND) Launches Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI
- Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
- Form 4 LIGAND PHARMACEUTICALS For: Mar 25 Filed by: Davis Todd C
- Form 4 LIGAND PHARMACEUTICALS For: Mar 05 Filed by: Sabba Stephen L
- Form 4 LIGAND PHARMACEUTICALS For: Mar 05 Filed by: Aryeh Jason
- Form 144 LIGAND PHARMACEUTICALS Filed by: Sabba Stephen L
Entities mentioned with LGND
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Roth Capital | View Related Stories »
- 13G | View Related Stories »
- IPO | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
